Notice2024-26780
Agency Forms Undergoing Paperwork Reduction Act Review
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 18, 2024
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 222 (Monday, November 18, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 222 (Monday, November 18, 2024)]
[Notices]
[Pages 90703-90705]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-26780]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-25-24HQ]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Division of Diabetes Translation
Programmatic & Participant User Experience Data Collection (DDTDC)'' to
the Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on July 26, 2024 to obtain
comments from the public and affected agencies. CDC received zero
comments related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to <a href="http://www.reginfo.gov/public/do/PRAMain">www.reginfo.gov/public/do/PRAMain</a>. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Division of Diabetes Translation Programmatic & Participant User
Experience Data Collection (DDTDC)--New--National Center for Chronic
Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The Division of Diabetes Translation (DDT) plays a crucial role in
helping prevent Type 2 diabetes, reducing diabetes complications and
disability, and reducing diabetes-related disparities across the United
States. DDT accomplishes this by providing education, training,
technical assistance (TA), and engaging in communication/marketing
activities for various key audiences. These customers include national,
state, and local partners, grantees, providers (e.g., lifestyle
coaches, diabetes educators, healthcare providers, health/medical and
community-based organizations), people with prediabetes, diabetes and
their family, friends, and caregivers, and other consumers of DDT
products and programs.
For DDT to be able to efficiently and effectively do this work and
fulfill its mission, it needs to be able to collect information and
feedback from intended audiences in a timely manner and with enough
frequency to ensure DDT can deliver clear, effective, efficient, and
appropriate customer service. This includes, for instance, collecting
data on key audiences' needs and on the reach, uptake, use, customer
experience and satisfaction with DDT's services, products, and related
programs, including its education, training, TA and communications
services and products.
However, in the interest of timely provision of services, DDT often
forgoes the important step of getting input from its key audiences on
the clarity, efficiency, effectiveness, and appropriateness of the
services and resources it develops and provides for them. Skipping this
information collection step, or doing so with less frequency, avoids
the delay involved in the standard OMB review process, but increases
the risk of DDT wasting both time and money developing and providing
education, training, TA, and communication/marketing that will not
achieve the intended objectives and will be unclear, irrelevant, or not
fully meet the needs of DDT's audiences. It can also have other
unintended consequences, such as jeopardizing the credibility of
Federal health officials.
The Division of Diabetes Translation Programmatic & Participant
User Experience Data Collection (DDTDC) will enable DDT to collect the
information they require in a timely manner to:
<bullet> Provide clear, effective, efficient, appropriate, and
timely education, communication, training, and technical
[[Page 90704]]
assistance to key audiences and other interested groups, including
consumer audiences (e.g., people with prediabetes, diabetes, and their
family, friends, and caregivers), providers (e.g., lifestyle coaches,
diabetes care and education specialists, healthcare and other
providers, health/medical and community-based organizations); and
partners (national, state, and local partners).
<bullet> Ensure quality and prevent duplication in the development
and dissemination of prevention and health information and program
activities by DDT to consumers, providers, and state and local
partners.
<bullet> Conduct exploratory/formative assessments to inform DDT's
development of education, communication/marketing, training, and
programmatic materials, tools, and resources to support and improve the
prevention and management of diabetes. For example, identifying key
audiences' knowledge, attitudes, behaviors, motivators, and information
needs.
<bullet> Assess the impact of programs, messages, educational and
training materials among recipients and determine to what extent they
meet relevant service-related DDT objectives and goals.
The following are examples of the areas of focus that the data
collection activities under this generic information collection
mechanism may include:
<bullet> Reach, uptake, use, customer experience, and satisfaction
with the CDC-recognized lifestyle change programs for type 2 diabetes
prevention, as well as related outcomes (e.g., participant retention
and recruitment rates).
<bullet> Satisfaction with CDC-recognized lifestyle change programs
toolkits, such as the Personal Success Tool and Champion toolkits.
<bullet> Reach, uptake, use, customer experience, and satisfaction
with diabetes education, type 2 prevention, and diabetes management
innovations (such as the Diabetes Self-Management Education and Support
services promotion initiative) and related short-term effects on
knowledge, awareness, practices (such as information seeking), and
outcomes (such as enrollment of people with diabetes or prediabetes).
<bullet> Reach, uptake, satisfaction, customer experience, and
short-term outcomes of CDC's training and technical assistance
resources (such as a webinar or online toolkit).
<bullet> Needs assessments for customer experience with,
utilization of, and short-term outcomes of technical assistance and
trainings for diabetes prevention and management.
<bullet> Understandability, ease of use, and appropriateness of
diabetes education messages, toolkits, programs, and marketing
materials.
<bullet> Exploratory assessments of knowledge, attitudes,
behaviors, beliefs, barriers, and facilitators to uptake and use of
lifestyle change programs for diabetes type 2 prevention and diabetes
management services and related innovations, resources, tools, and
materials.
Data collection methods proposed include, but are not limited to
in-depth individual interviews, cognitive interviews, intercept
interviews, group-based discussions (including focus groups and dyads/
triads), surveys or questionnaires, knowledge assessments,
observational assessments, and implementation and utilization data
reporting. Respondents would include key audiences and stakeholders of
CDC's work, including representatives of state and local DDT-funded
organizations; national, state, and local DDT partners (not CDC-
funded); providers of type 2 diabetes prevention and diabetes
management programs and services, including lifestyle coaches, diabetes
care and educations specialists, healthcare and other providers; heath/
medical and community-based organizations implementing programs and
services related to type 2 diabetes prevention and diabetes management;
people with--and at risk for--diabetes or with prediabetes; family,
friends, and caregivers of people with--and at risk for--diabetes or
with prediabetes.
As the methods for data collection and audiences may vary with each
request submitted under this proposed generic clearance, for each data
collection request unique instruments (e.g., surveys, interview guides)
will be developed to address the specific topics that information will
be collected on. Questions to be asked may focus, for example, on
collecting data on the audiences' needs and on the reach, uptake, use,
customer experience and satisfaction with DDT's services, products, and
programs. Such information will enable DDT to identify ways to improve
its services, products, and programs to better meet its audiences'
needs and achieve its mission of supporting the prevention of diabetes
and reducing diabetes-related complications and disparities across the
United States.
CDC requests a three-year approval for 6,000 burden hours for this
proposed Generic package. Based on projections, the estimated
annualized hourly burden anticipated for all data collection methods
would total 2,000 hours and include eight to ten data collection
activities over the course of a year. There is no cost to the
respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Number
Type of respondents Data collection respondents responses per Average burden
methods across methods respondent per response
----------------------------------------------------------------------------------------------------------------
Representatives of state and local Interviews; surveys or 4,000 1 30/60
DDT-funded organizations; national, questionnaires;
state, and local DDT partners (not knowledge
CDC-funded); providers of type 2 assessments;
diabetes prevention and diabetes motivation
management programs and services; assessments,
heath/medical and community-based observational
organizations implementing programs assessments;
and services related to type 2 implementation and
diabetes prevention and diabetes utilization data
management; people with--and at risk reporting.
for--diabetes or with prediabetes;
family, friends, and caregivers of
people with--and at risk for--
diabetes or with prediabetes.
----------------------------------------------------------------------------------------------------------------
[[Page 90705]]
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-26780 Filed 11-15-24; 8:45 am]
BILLING CODE 4163-18-P
</pre></body>
</html>Indexed from Federal Register on November 18, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.